Sage Therapeutics, Inc.

NASDAQ:SAGE

7.44 (USD) • At close January 14, 2025
Bedrijfsnaam Sage Therapeutics, Inc.
Symbool SAGE
Munteenheid USD
Prijs 7.44
Beurswaarde 455,129,352
Dividendpercentage 0%
52-weken bereik 4.62 - 27.675
Industrie Biotechnology
Sector Healthcare
CEO Mr. Barry E. Greene
Website https://www.sagerx.com

An error occurred while fetching data.

Over Sage Therapeutics, Inc.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase

Vergelijkbare Aandelen

InMode Ltd. logo

InMode Ltd.

INMD

16.07 USD

Twist Bioscience Corporation logo

Twist Bioscience Corporation

TWST

42.75 USD

AtriCure, Inc. logo

AtriCure, Inc.

ATRC

34.69 USD

Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc.

AMPH

38.48 USD

Bright Green Corporation logo

Bright Green Corporation

BGXX

0.073 USD

Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc.

RLAY

4.345 USD

Definitive Healthcare Corp. logo

Definitive Healthcare Corp.

DH

3.92 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)